Bris­tol My­ers li­cens­es for Evotec mol­e­cule for $20M; FDA ap­proves Im­pel's mi­graine nasal spray Trud­he­sa

Bris­tol My­ers Squibb has ex­er­cised its op­tion with Evotec for EVT8683, a small mol­e­cule cre­at­ed by the Ger­man biotech to tar­get a spe­cif­ic “cel­lu­lar stress re­sponse.”

The com­pa­nies have ob­tained clear­ance to start hu­man tri­als, close to 4.5 years af­ter ini­ti­at­ing a part­ner­ship.

Ac­cord­ing to an Evotec state­ment, “the pro­gramme tar­gets a key cel­lu­lar stress re­sponse mech­a­nism which has the po­ten­tial to de­liv­er dis­ease-mod­i­fy­ing treat­ments for sev­er­al dev­as­tat­ing neu­rode­gen­er­a­tive dis­eases.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER